RxDoctor Payments Data

Samvel Hmayakyan, MD

Family Medicine · Glendale, CANPI 1538168174

Payments from drug & device makers

$2,269in general payments, 2019–2025

Across 43 payments — averaging $52.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$356
  • Novo Nordisk$283
  • Edwards Lifesciences$278
  • Johnson & Johnson$252
  • Lilly USA, LLC$206
  • Ironwood Pharmaceuticals, Inc$169
  • plus $726 from 13 others

What the payments were for

  • Food & beverage$2,15395%
  • Education$1165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,269 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,283,696
Medicare patients
857
Services billed
17,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban844$329,449
VascepaIcosapent Ethyl1,137$294,536
LinzessLinaclotide481$255,778
OzempicSemaglutide259$245,371
JardianceEmpagliflozin414$235,900
Diclofenac Sodium770$234,942
IngrezzaValbenazine Tosylate47$224,196
JanuviaSitagliptin Phosphate425$196,481
CreonLipase/Protease/Amylase201$194,915
TradjentaLinagliptin392$160,886
JanumetSitagliptin Phos/Metformin Hcl251$130,116
ProliaDenosumab67$114,033
TrulicityDulaglutide93$89,598
EntrestoSacubitril/Valsartan123$70,591
Dexlansoprazole DrDexlansoprazole407$70,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$356$450,693682 claims
Novo NordiskOzempic$283$245,371259 claims
Lilly USA, LLCTrulicity, Mounjaro$206$136,518138 claims
AmgenProlia$23$114,03367 claims
Johnson & JohnsonXarelto, Procrit$252$72,305114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →